Anti-PD-1 Therapy is Beneficial for the Survival of Patients with Oral Squamous Cell Carcinoma

References

• Majchrzak E, Szybiak B, Wegner A, et al. Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature. Radiol Oncol. 2014;48(1):1–10. doi:10.2478/raon-2013-0057
   PubMed Web of Science ®Google Scholar
• Inaba H, Sugita H, Kuboniwa M, et al. Porphyromonas gingivalis promotes invasion of oral squamous cell carcinoma through induction of proMMP9 and its activation. Cell Microbiol. 2014;16(1):131–145. doi:10.1111/cmi.12211
   PubMed Web of Science ®Google Scholar
• Thomson PJ. Perspectives on oral squamous cell carcinoma prevention-proliferation, position, progression and prediction. J Oral Pathol Med. 2018;47(9):803–807. doi:10.1111/jop.12733
   PubMed Web of Science ®Google Scholar
• Sieviläinen M, Almahmoudi R, Al-Samadi A, Salo T, Pirinen M, Almangush A. The prognostic value of immune checkpoints in oral squamous cell carcinoma. Oral Dis. 2019;25(6):1435–1445. doi:10.1111/odi.12991
   PubMed Web of Science ®Google Scholar
• Chen Y, Li Q, Li X, et al. Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa. Oncoimmunology. 2018;7(2):e1388484. doi:10.1080/2162402X.2017.1388484
   PubMed Web of Science ®Google Scholar
• Jiang C, Yuan F, Wang J, Wu L. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages. Immunobiology. 2017;222(4):651–657. doi:10.1016/j.imbio.2016.12.002
   PubMed Web of Science ®Google Scholar
• Wu X, Gu Z, Chen Y, et al. Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J. 2019;17:661–674. doi:10.1016/j.csbj.2019.03.006
   PubMed Web of Science ®Google Scholar
• Lenouvel D, González-Moles MÁ, Ruiz-ávila I, Gonzalez-Ruiz L, Gonzalez-Ruiz I, Ramos-García P. Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: a systematic review and comprehensive meta-analysis. Oral Oncol. 2020;106:104722. doi:10.1016/j.oraloncology.2020.104722
   PubMed Web of Science ®Google Scholar
• Troiano G, Caponio V, Zhurakivska K, et al. High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: a meta-analysis of the literature. Cell Prolif. 2019;52(2):e12537. doi:10.1111/cpr.12537
   PubMed Web of Science ®Google Scholar
• Yao H, Wang H, Li C, Fang JY, Xu J. Cancer cell-intrinsic PD-1 and implications in combinatorial immunotherapy. Front Immunol. 2018;9:1774. doi:10.3389/fimmu.2018.01774
   PubMed Web of Science ®Google Scholar
• Sui H, Ma N, Wang Y, et al. Anti-PD-1/PD-L1 therapy for non-small-cell lung cancer: toward personalized medicine and combination strategies. J Immunol Res. 2018;2018:6984948. doi:10.1155/2018/6984948
   PubMed Web of Science ®Google Scholar
• Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495–499. doi:10.1038/nature22396
   PubMed Web of Science ®Google Scholar
• Zhang P, Ouyang S, Wang J, Huang Z, Wang J, Liao L. 程序性死亡分子1及其配体在口腔鳞状细胞癌患者外周血中的表达及临床意义. [Levels of programmed death-1 and programmed death ligand-1 in the peripheral blood of patients with oral squamous cell carcinoma and its clinical implications]. 华西口腔医学杂志 [Hua Xi Kou Qiang Yi Xue Za Zhi]. 2015;33(5):529–533. Chinese.
   PubMedGoogle Scholar
• Buchbinder EI, Dutcher JP, Daniels GA, et al. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer. 2019;7(1):49. doi:10.1186/s40425-019-0522-3
   PubMed Web of Science ®Google Scholar
• Tegos T, Tegos K, Dimitriadou A, Dimitriadis G. Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma. J Buon. 2019;24(4):1340–1353.
   PubMed Web of Science ®Google Scholar
• Kondoh N, Mizuno-Kamiya M, Umemura N, et al. Immunomodulatory aspects in the progression and treatment of oral malignancy. Jpn Dent Sci Rev. 2019;55(1):113–120. doi:10.1016/j.jdsr.2019.09.001
   PubMed Web of Science ®Google Scholar
• Sun Y, Liu N, Guan X, Wu H, Sun Z, Zeng H. Immunosuppression induced by chronic inflammation and the progression to oral squamous cell carcinoma. Mediators Inflamm. 2016;2016:5715719. doi:10.1155/2016/5715719
   PubMed Web of Science ®Google Scholar
• Lydiatt WM, Patel SG, O’Sullivan B, et al. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):122–137. doi:10.3322/caac.21389
   PubMed Web of Science ®Google Scholar
• Mandal R, Şenbabaoğlu Y, Desrichard A, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016;1(17):e89829. doi:10.1172/jci.insight.89829
   PubMed Web of Science ®Google Scholar
• Kansy BA, Concha-Benavente F, Srivastava RM, et al. PD-1 status in CD8(+) T cells associates with survival and Anti-PD-1 therapeutic outcomes in head and neck cancer. Cancer Res. 2017;77(22):6353–6364. doi:10.1158/0008-5472.CAN-16-3167
   PubMed Web of Science ®Google Scholar
• Mattox AK, Lee J, Westra WH, et al. PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4(+) TILs in the presence of PD-L1(+) TAMs. Cancer Res. 2017;77(22):6365–6374. doi:10.1158/0008-5472.CAN-16-3453
   PubMed Web of Science ®Google Scholar
• Weber M, Wehrhan F, Baran C, et al. PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma. Oncotarget. 2017;8(68):112584–112597. doi:10.18632/oncotarget.22576
   PubMedGoogle Scholar
• Malaspina TS, Gasparoto TH, Costa MR, et al. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunol Immunother. 2011;60(7):965–974. doi:10.1007/s00262-011-1007-5
   PubMed Web of Science ®Google Scholar
• Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111–1122. doi:10.1080/21645515.2019.1571892
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. doi:10.1146/annurev.immunol.26.021607.090331
   PubMed Web of Science ®Google Scholar
• Nishimura H, Agata Y, Kawasaki A, et al. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol. 1996;8(5):773–780. doi:10.1093/intimm/8.5.773
   PubMed Web of Science ®Google Scholar
• Sigel K, Dubrow R. CD4/CD8 ratio and lung cancer risk - Authors’ reply. Lancet HIV. 2017;4(3):e103–103e104. doi:10.1016/S2352-3018(17)30026-7
   PubMed Web of Science ®Google Scholar
• Yin Y, Qin J, Dai Y, Zeng F, Pei H, Wang J. The CD4+/CD8+ ratio in pulmonary tuberculosis: systematic and meta-analysis article. Iran J Public Health. 2015;44(2):185–193.
   PubMed Web of Science ®Google Scholar
• Tsukamoto H, Fujieda K, Miyashita A, et al. Combined blockade of IL6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res. 2018;78(17):5011–5022. doi:10.1158/0008-5472.CAN-18-0118
   PubMed Web of Science ®Google Scholar
• Zhu J, Liao M, Yao Z, et al. Breast cancer in postmenopausal women is associated with an altered gut metagenome. Microbiome. 2018;6(1):136. doi:10.1186/s40168-018-0515-3
   PubMed Web of Science ®Google Scholar
• Thompson ED, Zahurak M, Murphy A, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66(5):794–801. doi:10.1136/gutjnl-2015-310839
   PubMed Web of Science ®Google Scholar
• Tokito T, Azuma K, Kawahara A, et al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer. 2016;55:7–14. doi:10.1016/j.ejca.2015.11.020
   PubMed Web of Science ®Google Scholar
• Tian S, Jiang C, Liu X, et al. Hypermethylation of IFN-γ in oral cancer tissues. Clin Oral Investig. 2017;21(8):2535–2542. doi:10.1007/s00784-017-2052-z
   PubMed Web of Science ®Google Scholar
• Sharma M, Khong H, Fa’ak F, et al. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020;11(1):661. doi:10.1038/s41467-020-14471-1
   PubMed Web of Science ®Google Scholar
• Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375–2391. doi:10.1093/annonc/mdv383
   PubMed Web of Science ®Google Scholar